Slide source: www.FemaleSexualDysfunctionOnline.org.

Slides:



Advertisements
Similar presentations
for Bio-Identical Hormones
Advertisements

Androgens in the Aging Male The RxFiles May-June 2003 What the world needs is a little more testosterone!
Testosterone and 5-Alpha Reductase Inhibitors Stephen Chromi, PharmD PGY-1 Pharmacy Practice Resident St. Joseph’s/Candler Health System.
© 2013 North American Menopause Society. Menopause. 2013;20(9): Key points from the 2013 Position Statement of The North American Menopause Society.
Does Bio-Identical Hormone Compounding Help Alleviate Symptoms of Unbalanced Hormones? Julie Bryant Undergraduate Student Biology Department Tennessee.
THYROID DISEASE IN PREGNANCY: TREATING TWO PATIENTS Susan J. Mandel, MD MPH Perelman School of Medicine, University of Pennsylvania.
Pilot and Pharmacokinetic Studies of Solubilized Estradiol Administered Vaginally in a Softgel Capsule James H. Pickar, M.D., F.A.C.O.G.
Testosterone in Aging Men; Does menopause exist?
Depression—There are at least two sides to every story.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2013.
1 Efficacy of Testosterone Transdermal System (TTS) for Treatment of HSDD in Surgically Menopausal Women on Concomitant Estrogen Daniel Davis, MD, MPH.
Sexual Functioning Beyond Testosterone Rachel Hess, MD, MS
Sex and Aging John B. Pryor Department of Psychology Illinois State University.
Optimal Treatment for the Surgically Induced Menopausal Patient By Kerrie Hickman.
To treat or not to treat? Highly individualized. Debilitating symptoms. Mild symptoms.
Sex, Menopause, and Aging
MENOPAUSE 1.The cessation of menses is menopause.The climacteric and perimcnopausal are the periods of waning ovarian function.
Medical Therapy of Prostate Symptoms (MTOPS) Jeannette Y. Lee, Ph.D. University of Alabama at Birmingham.
11 Intrinsa ™ (testosterone transdermal system) Reproductive Health Drugs Advisory Committee Meeting Gaithersburg, MD December 2, 2004 Procter & Gamble.
METHODS This evidenced-based literature review compares the use of GnRHa therapy and laparoscopic ablation with respect to symptom relief, recurrence of.
A Comparison of the Effectiveness of Estrogen-Progesterone and Estrogen-Testosterone Combination Therapies in the Prevention of Osteoporosis in Postmenopausal.
By 2010, 45% of American women will be over age 50 Natl Center for Health Statistics.
M. Chantel Long, M.D. June 24,  Discuss and Define Sexual Dysfunction in Women  Review Causes  Provide Strategies to Improve Communication with.
All About T Testosterone for FTMs Presented by John Otto.
TEMPLATE DESIGN © Oocyte donation outcomes at Alpha International Fertility Centre IntroductionResultsConclusions References.
Medical Management of the Transgender Patient: for MHPs Vin Tangpricha M.D. Ph.D. Associate Professor of Medicine Emory University School of Medicine,
Pfizer Global Research & Development Sandwich CT13 9NJ Kent Introduction Sildenafil (Viagra  ) is an orally active, selective inhibitor of cGMP specific.
A Prospective Study of the Impact of Bladder Incontinence Surgery on Sexual Satisfaction K. Witzke, DO, Gregory McIntosh, DO, FACOS, Jeffrey Schock, DO,
Sex, quality of life at menopause and management Elizabeth Farrell Head, Menopause Unit, Monash Medical Centre, Clayton, & Director , Jean Hailes.
The Link between Oral Contraceptives Use and Increased Prevalence in Autism Spectrum Disorder Presentation by: Kim Strifert.
KIMBERLY CHEATHAM, MD, FACOG DIRECTOR, OU-TULSA PA PROGRAM OCTOBER 26, 2012 Hormone Replacement Therapy: A Primer for the Physician Assistant Modified.
Skin, the carotid artery and intervertebral discs: making the connection Mark P. Brincat.
Postmenopausal vaginal atrophy
Sprout Pharmaceuticals Inc. FDA Approval Date: August 18, 2015
Menopausal Hormone Replacement Professor Gordana Prelevic, MD, DSc, FRCP Consultant Endocrinologist Royal Free Hampstead NHS Trust Whittington Health.
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Care of the Transgender Patient Stephanie T. Page, MD, PhD Robert B. McMillen Professor in Lipid Research,
11 Androgenic AEs by Maximum Free T P hase II and Phase III % of patients Placebo N= 703 TTS Upper Decile N=58 Acne710.3 Alopecia Facial Hair55.2.
Bioidentical Hormones W hat Women Need to Know Presented by Daria C Yanez, MD Campus Chief at Riddle Hospital In collaboration with Beverly Vaughn, MD.
HYPOTHYROIDISM. INTRODUCTION  Hypothyroidism is defined as a deficiency in thyroid hormone secretion and action that produces a variety of clinical signs.
Testosterone Therapy Miami Testosterone Pellet Therapy & Hormone Replacement in Miami, Fort Lauderdale & Boca Raton by Rejuvchip As part of the normal.
Role of decreased androgens in the ovarian response to stimulation in older women Fertil Steril Jan;99(1):5-11 Presented by Hsing-Chun Tsai
Sexual Arousal and Response. Hormones involved in sexual arousal Steroid hormones : –Androgens (including testosterone) Produced by testes, adrenal glands,
Osphena® (ospemifene) Stefanie L Drahuschak University of Pittsburgh PharmD Candidate 2014.
Neurologic Effects Associated With Efavirenz Generally Mild, Transient Slideset on: Clifford DB, Evans S, Yang Y, et al. Impact of efavirenz on neuropsychological.
Ashley Bateman PGY 3.  Define the stages of female sexual response cycle.  Identify and define the types of female sexual dysfunction (FSD)  Understanding.
Sexuality and Aging Class 9 CSL November 8, 2016.
Bill Lynch The St George Hospital Sydney
2010 ASCO Breast Cancer Symposium Abstract 221
Pharmacokinetics, Clinical Efficacy, Safety Profile, and Patient-Reported Outcomes in Patients Receiving Subcutaneous Testosterone Pellets 900 mg for.
Fig. 1. Study enrollment and disposition of participants
Figure 1. Total (A) and free (B) T, estradiol (C), and SHBG (D) levels at baseline and during treatment. From: Testosterone Treatment and Sexual Function.
From: Safety and Efficacy of a Testosterone Metered-Dose Transdermal Spray for Treating Decreased Sexual Satisfaction in Premenopausal WomenA Randomized.
A Low Carbohydrate Nutritional Program Improves Weight, Insulin, and Estrogenic Parameters in Obese Patients with Estrogen Receptor Positive Endometrial.
Fig. 1. Serum levels of IGF-I vs
Chapter 65 Androgens 1.
First & second line treatments for ED
Naomi Swanson MD Department of OB/Gyn
James H. Liu, MD  The American Journal of Medicine 
Female Sexual Dysfunction (FSD)
Managing female sexual dysfunction
Efficacy and safety of transdermal testosterone in postmenopausal women with hypoactive sexual desire disorder: a systematic review and meta-analysis 
Original Article Testosterone for Low Libido in Postmenopausal Women Not Taking Estrogen Susan R. Davis, M.D., Ph.D., Michele Moreau, M.D., Robin Kroll,
Postmenopausal dehydroepiandrosterone administration increases free insulin-like growth factor-I and decreases high-density lipoprotein: a six-month trial 
Effects of treatment with testosterone alone or in combination with estrogen on insulin sensitivity in postmenopausal women  Hong Zang, M.D., Kjell Carlström,
SESSION 1 Context for the Current Study 9:10 am. Overview Session
Thomas M Price, M.D., Susan Allen, R.N., G.Vernon Pegram, M.D. 
Presentation transcript:

Slide source:

Testosterone Therapy for Hypoactive Sexual Desire Disorder

Slide source: Introduction  Rationale for use  Combination estrogen-testosterone therapy  Testosterone use in women – Therapies available and under investigation – Dosing/administration issues – Clinical trials of testosterone use in women – Managing side effects  Patient selection

Slide source: Rationale for Testosterone Therapy  Testosterone levels in women decline with aging – Women in their 40s have approximately one-half the level of women in their 20s  Women who undergo oophorectomy experience dramatic decreases in the level of testosterone – Level of testosterone decreases to one half of those prior to surgery Zumoff B, et al. J Clin Endocrinol Metab. 1995;80: Judd HL, et al. J Clin Endocrinol Metab. 1974;39:

Slide source: Rationale for Testosterone Therapy (cont’d)  Testosterone has been linked to sexual desire and coital frequency in menopausal women  Accumulating data indicate that testosterone therapy increases sexual function, including sexual desire, in postmenopausal women McCoy NL, et al. Maturitas. 1985;7: Shifren JL, et al. N Engl J Med. 2000;343: Lobo RA, et al. Fertil Steril. 2003;79:

Slide source: Combination Estrogen- Testosterone Therapy

Slide source: Impact of Estrogen Deficiency on Sexual Function  Changes in urogenital anatomy – Shortening and loss of elasticity of the vagina – Diminished secretions – Increased pH – Thinning of vaginal epithelial layers  Reduced blood flow  Reduced nerve transmission and discharge  Sleep disruption  Mood alterations Sarrel PM. Obstet Gynecol. 1990;75:26S-30S. Bachmann GA, et al. Menopause. 2004;11:

Slide source: Low Estrogen Is Associated With Increased Prevalence of Sexual Problems Sarrel PM. J Womens Health Gend Based Med. 2000;9:S25-S32. Sarrel PM. Obstet Gynecol. 1990;75:26S-30S. Percentage of Women Reporting Problems N=93; significance not reported.

Slide source: Simon J, et al. Menopause. 1999;6: N=93; *P≤0.05 EE=esterified estrogens; MT=methyltestosterone Placebo Low-Dose EE High-Dose EE Low-Dose EE + MT High-Dose EE + MT Postplacebo run-in period Month 1 Month 3 * * * ** * * * Efecto de Terapia con Estrógenos and Estrógenos- Andrógenos sobre Síntomas menopaúsicos

Slide source: Testosterone Use in Women

Slide source: Testosterone Therapies Available and Under Investigation Testosterone Therapies Available and Under Investigation *  Oral – Methyltestosterone – Testosterone undecanoate  Intramuscular – Testosterone propionate – Testosterone cypionate – Testosterone enanthate  Subcutaneous (implant) – Testosterone propionate pellets – Testosterone crystalline pellets  Transdermal – Transdermal testosterone patch – Testosterone gel – Testosterone emulsion – Testosterone spray  Other – Testosterone-containing vaginal ring – Sublingual testosterone in propylene glycol * Not approved by US Food and Drug Administration for use in women.

Slide source: Estrógenos y Enantato de Testosterona: Deseo sexual Sherwin BB, et al. Psychosom Med. 1987;49: Semanas B1234 Estrógeno + TE Control Estrógeno Inyeccion Niveles medios de Deseo Sexual N=65; TE=testosterona enantato

Slide source: Davis SR, et al. Maturitas. 1995;21: Estrogen Estrogen + testosterone Libido Activity Satisfaction Pleasure Fantasy Orgasm Relevancy Sexuality Score (Means of 6, 12, 18, and 24 Months) Summary Statistics N=34 Estradiol and Testosterone Implants: Sexual Function

Slide source: EEEE+MT Treatment difference Total Testosterone (ng/dL) Baseline Change from baseline (mean serum concentration) 20.8     6.8 P=0.02 Bioavailable Testosterone (pg/mL) Baseline Change from baseline (mean serum concentration) 3.1     2.0 P<0.010 Lobo RA, et al. Fertil Steril. 2003;79: EE=esterified estrogens; MT=methyltestosterone Estrogen and Methyltestosterone: Effect on Testosterone Levels N = 111 N = 107

Slide source: Lobo RA, et al. Fertil Steril. 2003;79: *P<0.02 vs baseline * EE+MT (n = 107) Study Week Mean Change EE (n = 111) Estrogen and Methyltestosterone: Sexual Desire EE=esterified estrogens; MT=methyltestosterone

Slide source: Estrogen and Methyltestosterone: Frequency of Interest/Desire Lobo RA, et al. Fertil Steril. 2003;79: *P<0.02 vs baseline; † P<0.01 vs baseline Study Week EE+MT (n = 107) EE (n = 111) * † † EE=esterified estrogens; MT=methyltestosterone

Slide source: Estrogen and Methyltestosterone: Sexual Functioning Sarrel PM, et al. J Reprod Med. 1998;43: EE=esterified estrogens; MT=methyltestosterone

Slide source: Estrogen and Testosterone Patch: Free and Bioavailable Testosterone Levels Shifren JL, et al. N Engl J Med. 2000;343: N=75; *P<0.001 for comparison with placebo Endocrine Sciences normal range for cycling women Placeb o Regimen (+CEE) 0 Regimen (+CEE) Free T (pg/mL) * * Bioavailable T (ng/dL) * * Baseline 300 mcg150 mcg CEE=conjugated equine estrogens; T=testosterone

Slide source: N=75; *P<0.05 for comparison with placebo Baseline 300 mcg 150 mcg Placebo Thoughts/ Desires Frequency Pleasure/ Orgasm Problems Percentage of Normative Mean * * Arousal Shifren JL, et al. N Engl J Med. 2000;343: Oral Estrogen and Testosterone Patch: Sexual Function

Slide source: Oral Estrogen and Testosterone Patch: Effect on Sexual Function Author (Year)Population (N) Treatment (Dose) Outcome (at 24 Weeks) Braunstein (2003) SM, HSDD (N=447) T patch (150, 300, 450 mcg/d) Placebo patch  Desire  Activity Davis (2003)SM, HSDD (N=77) T patch (300 mcg/d) Placebo patch  Desire  Activity Braunstein GD, et al. In: Program and abstracts of the 14th annual meeting of the North American Menopause Society; September 17-20, 2003; Miami Beach, Fla. Abstract 60. Davis S, et al. Fertil Steril. 2003;80(suppl 3):76. SM=surgically menopausal; HSDD=hypoactive sexual desire disorder; T=testosterone

Slide source: Oral Estrogen and Testosterone Patch: Effect on Sexual Function (cont’d) Author (Year)Population (N) Treatment (Dose) Outcome (at 24 Weeks) Simon (2004) SM, HSDD (N=562) T patch (300 mcg/d) Placebo patch  Desire  Activity Buster (2004) SM, HSDD (N=533) T patch (300 mcg/d) Placebo patch  Desire  Activity Simon JA, et al. Obstet Gynecol. 2004;103(suppl):64S. Buster J, et al. In: Program and abstracts of the 86th annual meeting of the Endocrine Society; June , 2004; New Orleans, La. Abstract OR44-6. SM=surgically menopausal; HSDD=hypoactive sexual desire disorder; T=testosterone

Slide source: Floter A, et al. Climacteric. 2002;5: N=50; EV-estradiol valerate; TU-testosterone undecanoate *P<0.05 vs EV at 24 weeks Estrogen and Testosterone Undecanoate: Sexual Function McCoy Sex Scale Score (Mean) * EV Baseline * * EV + TU Enjoyment of Sex Satisfaction With Frequency of Sex Interest in Sex

Slide source: Potential Side Effects With Testosterone Therapies  Hirsutism  Acne  Voice deepening  Alopecia  Liver toxicity  Negative effects on lipoproteins  Clitoromegaly

Slide source: Side Effects in Studies With Testosterone Therapies  Few side effects are reported in studies  Increased doses are associated with – Facial hair – Acne/oily skin  Oral preparations – Decreases in high-density lipoprotein Not seen with transdermal preparations

Slide source: N=75; *P<0.05 for comparison with placebo Hirsutism (Lorenzo Scale) Acne (Palatsi Scale) Facial Depilation (Times/Month) Mean Score (SEM) Baseline 300 mcg * 150 mcg Placebo Shifren JL, et al. N Engl J Med. 2000;343: Estrogen and Testosterone Patch: Safety

Slide source: Estrogen and Methyltestosterone: Safety EEEE+MT Hirsutism score (Lorenzo scale) Baseline score Change from baseline at week     2.2 Acne score (Palatsi scale) Baseline score Change from baseline at week    0.5 Lobo RA, et al. Fertil Steril. 2003;79: EE=esterified estrogens; MT=methyltestosterone

Slide source: Patient Selection  Testosterone therapy, in conjunction with estrogen therapy, may be indicated in women with: – Surgical menopause – Decreased libido – Diminished sense of well-being